Krystal Biotech, Inc.
KRYS
$313.66
+0.69%
Krystal Biotech is a commercial-stage, integrated biotechnology company that discovers, develops, manufactures, and commercializes genetic medicines for diseases with high unmet need, built on its proprietary HSV-1-based gene therapy platform. Its lead asset VYJUVEK is the first approved topical/re-dosable gene therapy for dystrophic epidermolysis bullosa, and the company has expanded commercialization into the United States, European Union, and Japan, giving it a rare profile among small-cap biotechs: a fully integrated, profitable, single-product commercial engine with an internal manufacturing footprint. The investor debate centers on whether VYJUVEK's durable revenue ramp can be extended into new indications and geographies before growth decelerates, and on the optionality embedded in the broader HSV-1 pipeline (including aesthetic and respiratory programs). Recent coverage highlights a strong earnings beat and impressive margins, but also flags softer near-term momentum and a cautious Hold-leaning view from some outlets, framing the stock as a high-quality but fully-valued commercial biotech awaiting its next catalyst.…
KRYS
Krystal Biotech, Inc.
$313.66
Related headlines
KRYS 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Krystal Biotech, Inc.'s 12-month outlook, with a consensus price target around $395.44 and implied upside of +26.1% versus the current price.
Average Target
$395.44
0 analysts
Implied Upside
+26.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$284 - $474
Analyst target range
Coverage is solid for a company of this size, with 9 analysts and a consensus recommendation of strong_buy (recommendation_mean of 1.25 on a 1-5 scale). The average target price is $395.44, implying roughly +26.9% upside from the current $311.50, and the consensus leans decisively bullish. Notably, the consensus EPS estimate of $35.42 is far above the trailing EPS of $0.03, which likely reflects a data inconsistency or a different share-count convention; investors should treat the target price and rating distribution as the reliable signals rather than the EPS estimate.
The target range runs from a low of $284.00 (about -8.8% downside) to a high of $474.00 (about +52.2% upside), a spread of roughly 67% of the current price that signals meaningful dispersion in assumptions. The high target likely embeds multiple expansion and pipeline optionality beyond VYJUVEK, while the low target prices in slower uptake, competitive pressure, or margin normalization. Institutional ratings show a consistent pattern of reiterations rather than fresh initiations: BofA, TD Cowen, HC Wainwright, Evercore ISI, Citigroup, and Guggenheim have all maintained Buy/Outperform ratings through 2026, with no downgrades in the provided history, which supports the bullish consensus but also raises the question of whether upgrades are already fully reflected in the price.
Drowning in data?
Find the real signal!
Bulls vs Bears: KRYS Investment Factors
The bull case rests on hard numbers: 31.95% YoY revenue growth, 94.57% gross margin, 48.07% net margin, $237.38M TTM free cash flow, and a debt-free balance sheet, all validated by a strong_buy consensus with a $395.44 average target (+26.9%). The bear case is not about business quality but about price and timing: 18.34x PS and 19.61x EV/Sales embed perfection, near-term momentum is negative (-8.85% over 1 month), and the flat 34.82x/34.80x trailing-to-forward PE pair shows the market doubts near-term earnings acceleration. On balance the bull evidence is stronger on fundamentals, but the bear evidence is stronger on near-term price action, which is why the stock is consolidating rather than breaking out. The single most important tension is whether VYJUVEK's revenue ramp can keep compounding at ~30% into new geographies and indications before the premium multiple compresses; resolution of that question, likely via the next few quarterly prints, is what will determine the next leg.
Bullish
- Revenue re-accelerating with sequential durability: Q1 2026 revenue of $116.36M grew 31.95% YoY versus $88.18M in Q1 2025, and the sequential cadence ($96.04M Q2'25, $97.80M Q3'25, $107.11M Q4'25, $116.36M Q1'26) shows four straight quarters of expansion. The 8.6% QoQ step-up argues VYJUVEK demand is durable rather than launch-stocking.
- Elite margins for a commercial biotech: Q1 2026 gross margin was 94.57% ($110.03M gross profit), operating margin 46.14%, and net margin 48.07% on $55.93M of net income. Gross margin even expanded from 89.81% in Q4 2025, reflecting the internal HSV-1 manufacturing model.
- Fortress balance sheet and strong FCF: Debt-to-equity is just 0.0077, current ratio 9.95, and cash was $501.31M at Q1 2026. TTM free cash flow of $237.38M with Q1 2026 FCF of $73.23M on only $7.15M capex gives ~91% FCF conversion of operating cash flow.
- Analyst consensus strongly bullish: 9 analysts carry a strong_buy consensus (mean 1.25 on a 1-5 scale) with an average target of $395.44, implying +26.9% upside from $311.50. BofA, TD Cowen, HC Wainwright, Evercore ISI, Citigroup and Guggenheim have all reiterated Buy/Outperform through 2026 with no downgrades.
Bearish
- Single-product concentration risk: The entire commercial engine rests on VYJUVEK, with no segment diversification disclosed. Any label, reimbursement, or competitive setback to one product would hit 100% of the $116.36M quarterly revenue base directly.
- Premium revenue multiples leave no margin for error: PS of 18.34x and EV/Sales of 19.61x sit far above the mid-single-digit to low-double-digit EV/Sales typical of profitable commercial biotech peers. EV/EBITDA of 33.92x prices in flawless execution.
- Near-term momentum has broken down: The stock is -8.85% over 1 month and -7.07% over 3 months, with relative strength of -7.83 and -9.92 points versus SPY. The latest session fell -2.70% on 270,092 shares, and the stock sits 18.6% below its $382.54 high.
- Flat forward PE signals growth skepticism: Trailing PE of 34.82x versus forward PE of 34.80x implies the market is not pricing meaningful near-term earnings acceleration, despite consensus revenue of $1.93B. That flatness is a warning that the growth embedded in estimates is not yet trusted.
KRYS Technical Analysis
KRYS is in a sustained, powerful uptrend on a 12-month basis, with a change_1y_pct of +67.07% versus the S&P 500's +13.13%, translating to relative_strength_1y of +53.94 percentage points. At the current price of $311.50, the stock sits roughly 81.4% of the way through its 52-week range of $183.26 to $382.54, i.e., about 18.6% below the high and 70% above the low. That positioning signals a stock that has retained most of its gains but is consolidating below its highs rather than pressing into breakout territory, a profile more consistent with digestion of a prior advance than with fresh momentum leadership. The max_drawdown of -17.63% confirms a controlled, orderly pullback rather than a trend break.
Short-term momentum has clearly decelerated and diverged from the longer-term trend: change_1m_pct is -8.85%, change_3m_pct is -7.07%, and change_6m_pct is +14.30%, while change_ytd_pct remains +26.16%. The 1-month relative strength of -7.83 points and 3-month relative strength of -9.92 points against a flat-to-down SPY (-1.02% and +2.85% respectively) show the stock is underperforming in the near term even as it outperforms over 12 months. This divergence is a classic mean-reversion signature after a strong run; the most recent session's -2.70% decline on volume of roughly 270,092 shares suggests sellers remain in control of the tape. RSI is not provided in the data, so momentum confirmation must rely on price action, which currently leans corrective.
Key technical levels are well defined: support sits at the 52-week low of $183.26, with intermediate support likely in the $300-$310 zone where the stock has repeatedly found buyers, while resistance is the 52-week high of $382.54. A decisive breakout above $382.54 would signal a resumption of the primary uptrend and likely invite momentum and index-adjacent flows, whereas a breakdown below $300 would put the $183.26 low in play and mark a material trend failure. The beta of 0.498 is a critical risk-management input: at roughly half the market's volatility, KRYS has historically been a low-beta, idiosyncratic biotech, meaning position sizing can be larger for the same dollar risk, but the elevated short_ratio of 12.53 days-to-cover also warns that positioning is crowded and squeeze-driven moves in either direction are possible.
Beta
0.50
0.50x market volatility
Max Drawdown
-17.6%
Largest decline past year
52-Week Range
$183-$383
Price range past year
Annual Return
+68.5%
Cumulative gain past year
| Period | KRYS Return | S&P 500 |
|---|---|---|
| 1m | -9.3% | -0.8% |
| 3m | -13.9% | +3.3% |
| 6m | +20.7% | +7.6% |
| 1y | +68.5% | +13.0% |
| ytd | +27.0% | +12.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KRYS Fundamental Analysis
Revenue is growing robustly and re-accelerating: Q1 2026 revenue of $116.36 million rose 31.95% year over year versus $88.18 million in Q1 2025, and the sequential cadence ($96.04M in Q2 2025, $97.80M in Q3 2025, $107.11M in Q4 2025, $116.36M in Q1 2026) shows four consecutive quarters of sequential expansion. The Q4 2025 to Q1 2026 step-up of 8.6% and the 31.95% YoY growth rate imply VYJUVEK demand remains durable rather than one-time launch stocking. With no segment breakdown provided, the investment case rests on a single-product concentration risk, but the trajectory supports the thesis that international expansion and label penetration are still early.
Profitability is exceptional for a commercial-stage biotech: Q1 2026 net income was $55.93 million on a net margin of 48.07%, gross margin was 94.57% (gross profit $110.03 million), and operating margin reached 46.14%. Margins have been stable-to-expanding, with gross margin moving from 89.81% in Q4 2025 to 94.57% in Q1 2026 and net margin holding near 48% versus 40.5% in Q1 2025. The Q3 2025 net margin of 81.15% was inflated by a $31.4 million tax benefit, so the underlying run-rate margin is closer to the 40-48% band; still, a ~40%+ operating margin on a gene therapy product is well above typical early-commercial biotech economics and reflects the company's internal manufacturing model.
The balance sheet is fortress-like: debt_to_equity is just 0.0077, current_ratio is 9.95, and cash stood at $501.31 million at Q1 2026, up from $496.30 million at year-end 2025. Free cash flow is strongly positive at $237.38 million TTM, with Q1 2026 FCF of $73.23 million on operating cash flow of $80.38 million and capex of only $7.15 million, giving an FCF conversion ratio of roughly 91% of operating cash flow. ROE of 16.80% and ROA of 9.37% confirm efficient capital deployment, and with cash flow coverage of debt at 8.82x, KRYS funds growth internally with essentially no financial leverage risk.
Quarterly Revenue
$116357000.0B
2026-03
Revenue YoY Growth
+31.9%
YoY Comparison
Gross Margin
94.6%
Latest Quarter
Free Cash Flow
$237383000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KRYS Overvalued?
Because net income is positive ($55.93 million in Q1 2026), the PE ratio is the appropriate primary metric. KRYS trades at a trailing PE of 34.82x and a forward PE of 34.80x, an essentially flat pair that implies the market is not pricing in meaningful near-term earnings acceleration from the current base, despite consensus revenue estimates of $1.93 billion. The PEG ratio of 0.27 is strikingly low and suggests that, if the growth embedded in consensus estimates materializes, the earnings multiple is cheap relative to growth; the tension is that the forward multiple's flatness signals skepticism about the durability of that growth.
On a peer basis, the stock screens expensive on revenue multiples: PS of 18.34x, EV/Sales of 19.61x, and EV/EBITDA of 33.92x, versus a biotechnology sector where profitable commercial-stage names typically trade in the mid-single-digit to low-double-digit EV/Sales range. The premium is justified by an unusual combination: 94.57% gross margin, 46.14% operating margin, 48.07% net margin, and 31.95% revenue growth, which are elite metrics for the sector. The PB ratio of 5.85x is moderate and reflects a capital-light, high-return asset base rather than balance-sheet leverage, so the premium is fundamentally defensible but leaves little room for execution error.
Historically, KRYS's own valuation band has compressed dramatically as earnings arrived: the PE ratio was 1467x in Q1 2024 and 100x in Q4 2023, versus 34.82x today, while the PS ratio has fallen from 110.10x in Q1 2024 to 18.34x now. The stock is therefore near the low end of its own historical multiple range, which is the classic signature of a company that has grown into its valuation rather than one that has de-rated on deteriorating fundamentals. The risk is that the market's willingness to pay a premium multiple has structurally reset lower as the company matures from story stock to earnings compounder.
PE
34.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 10x~100x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
33.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risk is low but concentrated. The company carries essentially no leverage (debt-to-equity 0.0077, current ratio 9.95, $501.31M cash) and generates $237.38M TTM free cash flow, so solvency is not a concern. The real financial risk is revenue concentration: 100% of the $116.36M Q1 2026 revenue comes from VYJUVEK, so any pricing, reimbursement, or uptake disappointment in the US, EU, or Japan flows straight to the P&L. Margin quality also warrants scrutiny: the Q3 2025 net margin of 81.15% was inflated by a $31.4M tax benefit, and the underlying 40-48% net margin band depends on sustaining 94%+ gross margins from internal manufacturing.
Market and competitive risks center on valuation compression. At 18.34x PS and 19.61x EV/Sales, KRYS trades at a steep premium to profitable commercial biotech peers in the mid-single-digit to low-double-digit EV/Sales range, so any deceleration in the 31.95% growth rate could trigger multiple contraction faster than earnings grow. The beta of 0.498 means the stock is only half as sensitive to broad market moves as the S&P 500, so macro rotation is a secondary risk; the primary risk is idiosyncratic. Competitive and pipeline risk is real: the thesis depends on extending VYJUVEK into new indications and on optionality from the HSV-1 pipeline (aesthetic and respiratory programs), and a clinical or regulatory setback there would remove the growth premium. Recent coverage reinforces the caution, with Zacks maintaining a Hold and citing poor momentum despite a strong earnings beat.
In a worst-case scenario, slower VYJUVEK uptake plus multiple compression toward peer levels could take the stock back toward its 52-week low of $183.26, roughly -41% from the current $311.50, which is also close to the analyst low target of $284.00 (-8.8%) only in the mild version of the scenario. A more realistic adverse path is a break below the $300-$310 support zone, which would put the $183.26 low in play and represent a material trend failure; the observed max drawdown of -17.63% shows the stock can correct sharply even in an intact uptrend. The crowded short interest (12.53 days-to-cover) amplifies downside velocity if sentiment turns.